

## Case report

# Guillain–Barré syndrome after allogeneic bone marrow transplantation: Case report and literature review



Tomoko Yoshida MD<sup>a</sup>, Yoshino Ueki MD<sup>a,\*</sup>, Tomotaka Suzuki MD<sup>b</sup>, Yuichi Kawagashira MD<sup>c</sup>, Haruki Koike MD<sup>c</sup>, Shigeru Kusumoto MD<sup>b</sup>, Shinsuke Ida MD<sup>b</sup>, Takuya Oguri MD<sup>a</sup>, Masahiro Omura MD<sup>a</sup>, Gen, Sobue MD<sup>c</sup>, Noriyuki Matsukawa MD<sup>a</sup>

<sup>a</sup> Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Science, Kawasumi, Mizuho-ku, Nagoya 467-8601, Japan

<sup>b</sup> Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Science, Kawasumi, Mizuho-ku, Nagoya 467-8601, Japan

<sup>c</sup> Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-Ku, Nagoya 466-8550, Japan

## ARTICLE INFO

## Article history:

Received 5 January 2016

Received in revised form 3 August 2016

Accepted 3 August 2016

Available online 4 August 2016

## Keywords:

Acute inflammatory demyelinating polyneuropathy  
Allogeneic bone marrow transplantation  
Guillain–Barré syndrome  
Intravenous immunoglobulin

## ABSTRACT

A 50-year-old man with acute myelogenous leukemia underwent allogeneic bone-marrow transplantation (BMT). He presented with severe diarrhoea 86 days post BMT and was diagnosed with graft-versus-host disease (GVHD) based on skin and rectal biopsies. He complained of numbness and weakness in the distal extremities at 114 days after BMT. His symptoms rapidly deteriorated and he required mechanical ventilation for respiratory failure. His clinical course and the findings of a nerve conduction study fulfilled the criteria for diagnosis of Guillain–Barré syndrome (GBS). Sural nerve biopsy revealed active demyelination and infiltration of macrophages and CD8<sup>+</sup> T-cells. After three cycles of intravenous immunoglobulin therapy, his symptoms gradually improved, and he could eventually walk unassisted. Although GBS has been known to develop after allogeneic BMT, the pathogenesis remains unclear, and specific treatment regimens have not been well established. Here, we report a case of GBS, caused by an immune-mediated mechanism related to GVHD, which was successfully treated using intravenous immunoglobulin therapy.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Guillain–Barré syndrome (GBS) is an acute neurological disorder that is characterized by rapid progressive, symmetrical weakness of the extremities. GBS consists of at least 4 subtypes of acute peripheral neuropathy, of which the most common form is acute inflammatory demyelinating polyradiculoneuropathy (AIDP) [1].

Peripheral neuropathy is an uncommon complication of allogeneic bone marrow transplantation (BMT) and 4% of cases develop neuropathy within the first 3 months after BMT [2]. Most peripheral neuropathies after allogeneic BMT are of the AIDP subtype [2–6], possibly due to the increased susceptibility to infections and defects in both cell-mediated and humoral immunity. AIDP typically occurs in the clinical setting of graft-versus-host-disease (GVHD) where immunologically competent donor T-cells and/or autoantibodies attack host tissues [2]. However, the number of patients and neuropathological evaluations reported to date are too limited to suggest specific regimens for treatment.

Here, we report a patient with GBS whose neurophysiological findings revealed an AIDP pattern and whose pathological findings confirmed infiltration of macrophages and CD8<sup>+</sup> T-cells caused by immune-mediated mechanism related to GVHD. He was effectively treated using 3 rounds of intravenous immunoglobulin and had a good prognosis.

## 2. Materials and methods

## 2.1. Neuropathology

Right sural nerve biopsy was performed 41 days after the onset of neurological symptoms. The specimen was divided into 2 portions. One portion was fixed in 2.5% glutaraldehyde in 0.125 M cacodylate buffer (pH 7.4) and embedded in epoxy resin for morphometric and ultrastructural studies. The density of myelinated fibres was assessed using toluidine blue staining. Another fraction was processed for a teased-fibre study. The second portion of the specimen was fixed in 10% formalin and paraffin embedded. Following sectioning, the tissue was stained with haematoxylin and eosin and the Kluver–Barrera method. Immunohistochemical studies were performed on consecutive, deparaffinised sections using the following antibodies: mouse monoclonal anti-CD4, anti-CD8, anti-CD68, and anti-CD20 (Dako).

Abbreviations: Ara-C, cytarabine; BU, busulfan; HDAC, high-dose cytarabine; IDA, idarubicin; MTX, methotrexate; PSL, prednisolone.

\* Corresponding author.

E-mail address: [yueki@med.nagoya-cu.ac.jp](mailto:yueki@med.nagoya-cu.ac.jp) (Y. Ueki).

2.2. Literature review

Two independent investigators (YT and YU) searched PubMed on January 20, 2016, using the term “allogeneic bone marrow transplantation”, “hematopoietic stem cell transplantation” AND each of the following terms: “Guillain-Barre syndrome”, “neuropathy” and “neurological complication”. Only papers written in English were included. Additional articles were sourced manually by searching the citations of relevant articles. We included 10 full-text articles that described patients who developed GBS after BMT [3–12] (Table 1) and 2 clinical review articles [13,14].

3. Case report

A 50-year-old man was diagnosed with acute myelogenous leukemia (FAB M0 with a complex chromosomal anomaly). Following induction chemotherapy (IDA and Ara-C), 3 cycles of consolidation therapy (HDAC), intrathecal chemotherapy (MTX, Ara-C, and PSL) and conditioning chemotherapy (cyclophosphamide and BU), an allogeneic BMT was performed with his HLA-matched older brother acting as donor. As prophylaxis for GVHD, cyclosporine and MTX were administered. On day 68 after BMT, he presented erythema exudative multiforme, followed by severe diarrhoea on day 86, and was diagnosed with acute GVHD (Grade III) based on skin and rectal biopsies. After he was treated with PSL (60 mg; 1 mg/kg bodyweight), his symptoms gradually improved to Grade II, and the dosage of PSL was gradually reduced to 20 mg. The neurological symptoms began on day 114 after BMT where he complained of numbness in his distal upper and lower extremities and difficulty in swallowing. The weakness of his extremities rapidly increased and on day 116 he required mechanical ventilation for respiratory failure. Neurological examination revealed complete tetraplegia and absence of deep tendon reflexes. He showed hyperesthesia in his distal upper and lower extremities.

Serological tests revealed no abnormalities. Although serological markers for Epstein-Barr virus, herpes simplex virus (HSV), varicella-zoster virus (VZV), HIV, mycoplasma, listeria, and *Campylobacter jejuni* were negative, pp65 cytomegalovirus (CMV) antigenaemia was positive (14/50,000 cells). We repeated tests for CMV antigenaemia once a week; and the tests became negative after the use of ganciclovir for 1 month after the onset of neurological symptoms. His anti-ganglioside antibodies, including GM1IgG, were all negative. His cerebrospinal fluid (CSF) showed a mild increase in cells (19/ $\mu$ l) and an elevation in protein levels (118 mg/dl). Polymerase chain reaction on the CSF was also negative for HSV, VZV, and CMV both at the onset of neurological symptoms and 1 month thereafter. Two days after the onset of neurological symptoms, nerve conduction studies showed delayed motor nerve conduction velocity (left median nerve: 31.7 m/s, ulnar nerve: 41.8 m/s, tibial nerve: 24.8 m/s) with temporal dispersion and decreased amplitude of compound muscle action potential (left median nerve: 420  $\mu$ V, ulnar nerve: 640  $\mu$ V, tibial nerve: 230  $\mu$ V). F waves and sensory nerve action potentials could not be evoked. His cervical and lumbar MRI showed no abnormal lesions.


In semi-thin cross sections, the total myelinated fibre densities were moderately decreased (Fig. 1a). Myelin ovoids and endoneurial oedema were observed. There was no evidence of vasculitis or abnormal deposits. Teased-fibre studies showed that the frequency of segmental de/remyelination and axonal degeneration was 30.4% and 15.2%, respectively (Fig. 1b). Scattered lymphocytes and numerous macrophages were detected in the parenchyma. Immunohistochemical studies confirmed infiltration of CD8-positive cytotoxic T-cells and CD68-positive macrophages (Fig. 1c and d). These neurophysiological and pathological findings were compatible with the diagnosis of AIDP.

The patient was treated with 2 courses of intravenous immunoglobulin (IVIg, 400 mg/kg per day) for 5 days; however, his symptoms remained unchanged. As a treatment of GBS, we also considered plasma

**Table 1**  
Analysis of the patients who developed GBS after allogeneic BMT.

Age/gender	Tumor	GVHD (at the time of GBS)	GBS on set after BMT	CMV antigenemia	Treatment	Outcome	Cause
50/male	AML	Chronic GVHD	114 days	(+)	IVIg	Recovery	GVHD > CMV
64/male	WM	Unclear		(-)	IVIg	Alive	
59/male	AML	Unclear		(-)	IVIg, rituximab	Not known	
37/male	AML	Unclear		(-)	IVIg	Alive	
44/female	MDS	Unclear		(+)	IVIg, rituximab	Alive	
58/female	NHL			(-)	Steroids, IVIg, plasmapheresis, cyclosporin	Recovery following cyclosporin	Discontinuation of immunosuppressant, GVHD
58/male	MDS	Possible chronic GVHD	69 days	(-)	IVIg, rituximab, steroids	Alive	Possible GVHD
34/female	ALL	Acute GVHD	78 days	(+)	IVIg, cyclosporin	Recovery	Immune-mediated GVHD
40/female	CML	Acute GVHD			Steroids, cyclosporin, IVIg, plasmapheresis	Partial initial improvement but ultimate death	GVHD
18-60	MDS		142 days	(+)	IVIg	Death following respiratory failure	
18-60	NHL	Chronic GVHD	160 days	(+)	IVIg, rituximab, plasmapheresis	Death following respiratory infection	
18-60	AML	Possible chronic GVHD	101 days	(+)	No specific treatment	Death following respiratory failure	
16/male	T cell ALL		6 days	(-)	IVIg	Death	Ara-C treatment prior to transplantation
17/male	T cell Lymphoma		3 days	(-)	IVIg	Death	Ara-C treatment prior to transplantation
18/male	T cell ALL		2 days	(-)	IVIg	Death	Ara-C treatment prior to transplantation
34/female	CML	No GVHD	120 days		Plasmapheresis	Improvement	
27/male	HD	No GVHD	450 days		Plasmapheresis	Recovery	
34/male	AML	Mild GVHD	120 days		Plasmapheresis	Improvement	
59/female	CML	Mild GVHD	330 days	(-)	IVIg, plasmapheresis	Death	
43/male	CML	Acute GVHD	163 days	(+)	IVIg, plasmapheresis	Very slight neurological deficiency	HHV-6
23/male	AML	No GVHD	42 days		IVIg, plasmapheresis	Death	CMV

GVHD—graft versus host disease; BMT—bone marrow transplant; CVM—cytomegalovirus; AML—acute myeloid leukemia; CML—chronic myeloid leukemia; MDS—myelodysplastic syndrome; NHL—Non-Hodgkin's Lymphoma; HD—Hodgkin's disease; WM—Waldenstrom macroglobulinemia; ALL—acute lymphoblastic leukemia; IVIg—intravenous immunoglobulin.



**Fig. 1.** Pathological findings of right sural nerve biopsy. Toluidine blue stain showing loss of myelinated fibres and myelin ovoids. Large fibres and small fibres were both impaired (a). Teased-fibre preparations revealed marked segmental demyelination (b). Immunostaining showed infiltration of CD8<sup>+</sup> T-cells (c) and severe infiltration of CD68<sup>+</sup> cells (d).

exchange (PE), given the severity of his motor symptoms. However, since his general status was not good and he presented thrombocytopenia (PLT  $27\text{--}58 \times 10^3/\mu\text{l}$ ), we decided against PE. Muscle strength gradually improved after the third round of IVIG therapy, and ventilator weaning was possible at 86 days after the onset of neurological symptoms. He was able to walk with assistance 130 days after the onset of neurological symptoms, and eventually regained the ability to walk without assistance.

#### 4. Discussion

We here reported on a male patient who developed severe peripheral neuropathy at the time of recovery from acute GVHD after allogeneic BMT, when immunosuppression therapy was gradually attenuated. Although symptoms of acute GVHD, such as erythema exudative multiforme and diarrhoea had improved, neurological symptoms presented on day 114 after BMT. Based on the diagnostic criteria of acute and chronic GVHD, he was diagnosed with overlap syndrome since the neurological symptoms newly occurred more than 100 days after BMT [15]. Toxins, infection, and critical illness polyneuropathy were excluded as causes in the present case and neurophysiological and neuropathological findings were compatible with a diagnosis of AIDP. He was successfully treated with 3 rounds of IVIG.

Peripheral neuropathy appears to be a rare complication of BMT that can develop as early as 2 days and up to 15 months after BMT [3,7]. Wen et al. reviewed several studies that reported the presentation of GBS following allogeneic BMT and proposed several mechanisms for the pathogenesis of GBS after BMT including the development of an aberrant immunological response to infections, drug toxicity, and a possible manifestation of GVHD [3]. Fujisaki proposed that the mechanism of GBS after allogeneic BMT was not direct neural involvement by CMV and humorally mediated cross-reaction, but rather peripheral expansion of T-cells following CMV infection [5]. We reviewed the recent developments in the field in order to better understand the pathogenesis of GBS following BMT (Table 1).

Previous studies found that 6 of 11 patients were positive for serological markers of *Campylobacter jejuni* or CMV and 4 of these 6 patients

presented with some form of GVHD [3]. One study of 85 patients reported that 3 patients with GBS after BMT, who presented with EBV or CMV infection, 1 of which was diagnosed with GVHD [4]. Peripheral neuropathy has been shown to occur in the clinical course of GVHD. In 1 case, an allogeneic BMT patient developed GBS as the leading manifestation of GVHD subsequent to discontinuation of immunosuppressive medication with cyclosporine; resumption of immunosuppressive medication improved the patient's condition [6]. In the present study, the symptoms developed almost 6 months after chemotherapy and biopsy results indicated GVHD, which was then treated with immunosuppression therapy. Since it occurred during the timing when PSL as a treatment of acute GVHD was reduced, an immune-mediated mechanism related to GVHD seemed plausible. In addition, while the titre was low and there were no symptoms of viral infection, the patient was positive for the CMV antigen and these tests became negative at 1 month after starting treatment with ganciclovir. We cannot totally exclude the involvement of CMV infection as a factor of GBS in the present patient. Therefore, an immune-mediated mechanism related to GVHD, and to some extent, CMV infection, appeared to be the most likely cause of GBS in the present case.

While many histopathological studies have been performed for GBS cases after BMT, only 2 studies have performed immunohistochemical analysis on sural nerve biopsies. In 1 case, an axonal type of GBS was preceded by CMV infection without clinical symptoms of GVHD, where axonal loss and infiltration of plasma cells was detected [4]. In the other case, the axonal type of GBS was preceded by CMV infection after acute GVHD and infiltration of CD8<sup>+</sup> T-cells and macrophages were detected [5]. Similarly, in our study, CD8<sup>+</sup> T-cell and macrophage infiltration were detected along with active demyelinating patterns and axonal degeneration. Thus, our results suggest that CD8<sup>+</sup> T-cell activation may play an important role in the pathophysiology of GBS at the time of recovering from acute GVHD after BMT.

Most patients who develop GBS post-transplant recover after treatment with IVIG and/or PE [3,8]. Usually, neurological symptoms gradually improve within 1 to several months after these treatments [3,11]. In 1 report, although muscle strength remained unchanged after IVIG by day 88 after neurological symptom onset, the patient displayed rapid recovery of muscle strength by day 150 [5]. In some cases, the

combination of IVIG and rituximab appeared to have a better outcome [8,9]. Thone et al. have reported 1 case of GBS after BMT who was treated with cyclosporine after a poor response to IVIG and PE [6]. In that case, the patient required artificial ventilation at 18 days after the neurological symptom onset. Following cyclosporine treatment initiation at day 26, his symptoms improved markedly and he was weaned off artificial ventilation by 14 days later. However, in a case report of GBS associated with CMV infection after allogeneic hematopoietic stem cell transplantation and in a review of GBS after allogeneic hematopoietic stem cell transplantation, the outcome of GBS was poor, and all patients ( $n = 4$ ) died after respiratory and/or multisystem failure 1–5 months after transplant [12,13]. In the present study, the patient was treated with cyclosporine, MTX, as well as PSL for GVHD. While the GVHD symptoms, such as severe diarrhoea and mild skin rash, improved with this approach, the GBS symptoms persisted. After treatment with repetitive IVIG, his prognosis was good. Since the mechanism of GBS after allogeneic BMT may vary, a combined treatment approach of treating infection and GVHD with IVIG and/or PE seems to be effective. Several rounds of IVIG may be useful for severe forms of GBS after allogeneic BMT.

### Conflict of interest

The authors declare that there are no conflicts of interest.

### References

- [1] R. Hughes, D. Cornblath, Guillain-Barré syndrome, *Lancet* 366 (2005) 1653–1666.
- [2] R.A. Patchell, Neurological complications of organ transplantations, *Ann. Neurol.* 36 (1994) 688–703.
- [3] P.Y. Wen, E.P. Alyea, D. Simon, et al., Guillain-Barre syndrome following allogeneic bone marrow transplantation, *Neurology* 49 (1997) 1711–1714.
- [4] I. Avivi, S. Chakrabarti, P. Kottaridis, et al., Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation, *Bone Marrow Transplant.* 34 (2004) 37–42.
- [5] G. Fujisaki, M. Kami, N. Murashige, et al., Guillain-Barré syndrome associated with rapid immune reconstitution following allogeneic hematopoietic stem cell transplantation, *Bone Marrow Transplant.* 37 (2006) 617–619.
- [6] J. Thone, S. Lamprecht, A. Hohaus, et al., Guillain-Barre syndrome as leading manifestation of Graft-versus-Host Disease in an allogeneic bone marrow transplanted patient, *J. Neurol. Sci.* 292 (2010) 114–116.
- [7] V. Rodriguez, I. Kuehnle, H.E. Heslop, et al., Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation, *Bone Marrow Transplant.* 29 (2002) 515–517.
- [8] A.M. Delios, M. Rosenblum, A.A. Jakubowski, et al., Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease, *J. Neuro-Oncol.* 110 (2012) 251–256.
- [9] F. Ostronoff, M.A. Perales, M.D. Stubblefield, et al., Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT, *Bone Marrow Transplant.* 42 (2008) 71–72.
- [10] B. Nasilowska-Adamska, Z. Lysiak, K. Halaburda, et al., Guillain-Barre syndrome—pathological connection with GvHD after allogeneic bone marrow transplantation, *Ann. Transplant.* 11 (2006) 10–11.
- [11] A. Tomaszewska, B. Nasilowska-Adamska, T. Dzieciatkowski, et al., Simultaneous human herpesvirus 6-associated encephalitis and Guillain-Barre syndrome in a patient after matched unrelated donor haematopoietic stem cell transplantation, *Arch. Med. Sci.* 6 (2010) 288–290.
- [12] J.C. Hernandez-Boluda, M.J. Lis, R. Goterris, et al., Guillain-Barre syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation, *Transpl. Infect. Dis.* 7 (2005) 93–96.
- [13] O. Grauer, D. Wolff, H. Bertz, et al., Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease, *Brain* 133 (2010) 2852–2865.
- [14] K.M. Ruzhansky, T.H. Brannagan, Neuromuscular complications of hematopoietic stem cell transplantation, *Muscle Nerve* 52 (2015) 480–487.
- [15] A.H. Filipovich, D. Weisdorf, S. Pavletic, et al., National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, *Biol. Blood Marrow Transplant.* 11 (2005) 945–956.